Hormone identified that limits liver fibrosis

October 13, 2016, Kobe University
The application of IGF-I for the treatment of NASH and liver cirrhosis. Credit: Nishizawa H, Takashi Y et al.

Nonalcoholic steatohepatitis (NASH) has been emerging worldwide and effective treatment, especially for liver fibrosis, is essential for improving the prognosis. A Japanese research team has identified and clarified the mechanism for a hormone that limits the fibrosis associated with NASH and cirrhosis. This discovery has potential applications for the treatment of these conditions. These findings were published on October 10 in the online version of Scientific Reports.

The research group was led by Associate Professor TAKAHASHI Yutaka (Division of Diabetes and Endocrinology, Department of Internal Medicine, Graduate School of Medicine) and medical research fellow NISHIZAWA Hitoshi (Division of Diabetes and Endocrinology, Kobe University Hospital).

NASH is a progression of nonalcoholic fatty liver disease (NAFLD) in the context of obesity and diabetes, resulting in fatty deposits, inflammation and fibrosis. In some cases fibrosis develops into or liver cancer, shortening life expectancy. NAFLD is closely associated with metabolic syndrome, and cases of NASH are increasing along with obesity and diabetes - an estimated three to four million patients in Japan currently suffer from NASH. It is becoming a serious public health issue. Liver fibrosis (including its manifestation in liver cirrhosis) is strongly associated with increased mortality, so the development of drugs to control fibrosis is a pressing issue. However, current medicines only have limited effectiveness.

The prevalence of fatty liver and NASH are very high in patients with (GH) deficiency, and the research group has demonstrated that this was caused by a lack of insulin-like growth factor-I (IGF-I), which is mainly induced by growth hormone. The group has further proved that administering growth hormone alleviated the NASH conditions caused by adult growth hormone deficiency, and treatments of GH and IGF-I were effective when applied to model animals with growth hormone deficiency.

In order to clarify the potential clinical applications of IGF-I on common forms of NASH and liver cirrhosis, they investigated its effectiveness on animal models, and discovered that it was drastically effective in improving the characteristics of NASH, especially fibrosis. First, they used a model mouse suffering from obesity-related NASH to test the effects of IGF-I. After one month of administering IGF-I, they noted drastic positive changes in the characteristics of NASH: fatty deposits, inflammation and fibrosis. In a model mouse, who had developed liver cirrhosis, they also noted ameliorations in fibrosis. After investigating the mechanism behind this, they discovered that IGF-I acts on hepatic stellate cells, which play a key role in the development of fibrosis. IGF-I suppresses the activation of these cells by causing cellular senescence and consequently preventing fibrosis. IGF-I also improved mitochondrial function and oxidative stress in the liver (both causes NASH), alleviating and inflammation.

Medication that suppresses NASH-related and other complications is currently very limited. These findings suggest that IGF-I can be used to prevent the development of fibrosis, and thus improve prognosis and alleviate complications for sufferers of NASH and cirrhosis. IGF-I may also be effective on models for cirrhosis related with viral hepatitis, because the activation of stellated cells is a common pathway to fibrosis. The unique mechanism for IGF-I has been clarified, and combination with other medications could potentially lead to a breakthrough in medical treatment for fibrosis.

Explore further: Technique may identify patients with fast-progressing fibrosis in nonalcoholic fatty liver disease

More information: Hitoshi Nishizawa et al, IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner, Scientific Reports (2016). DOI: 10.1038/srep34605

Related Stories

Technique may identify patients with fast-progressing fibrosis in nonalcoholic fatty liver disease

October 11, 2016
Combining multiple non-invasive measures, researchers at University of California San Diego School of Medicine describe a novel method to quantify the progression of nonalcoholic fatty liver disease (NAFLD) to its more dangerous ...

Simple blood test could vastly improve detection rates of severe liver disease

October 6, 2016
A new non-invasive method of predicting the risk of developing a severe form of liver disease could ensure patients receive early and potentially life-saving medical intervention before irreversible damage is done.

Estrogen protects women with NASH from severe liver fibrosis

October 29, 2013
New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis. According to the study published online in Hepatology, a journal of the American Association for the ...

NASH associated with a 50 percent higher chance of death compared with NAFLD

April 24, 2015
Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those ...

Coffee consumption reduces fibrosis risk in those with fatty liver disease

February 2, 2012
Caffeine consumption has long been associated with decreased risk of liver disease and reduced fibrosis in patients with chronic liver disease. Now, newly published research confirms that coffee caffeine consumption reduces ...

Existing diabetes drug shows effectiveness against chronic liver disease

June 21, 2016
Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants.

Recommended for you

New blood test to detect liver damage in under an hour

May 24, 2018
A quick and robust blood test that can detect liver damage before symptoms appear has been designed and verified using clinical samples by a team from UCL and University of Massachusetts.

Selective neural connections can be reestablished in retina after injury, study finds

May 24, 2018
The brain's ability to form new neural connections, called neuroplasticity, is crucial to recovery from some types of brain injury, but this process is hard to study and remains poorly understood. A new study of neural circuit ...

Space-like gravity weakens biochemical signals in muscle formation

May 23, 2018
Astronauts go through many physiological changes during their time in spaceflight, including lower muscle mass and slower muscle development. Similar symptoms can occur in the muscles of people on Earth's surface, too. In ...

Eating at night, sleeping by day swiftly alters key blood proteins

May 21, 2018
Staying awake all night and sleeping all day for just a few days can disrupt levels and time of day patterns of more than 100 proteins in the blood, including those that influence blood sugar, energy metabolism, and immune ...

Hotter bodies fight infections and tumours better—researchers show how

May 21, 2018
The hotter our body temperature, the more our bodies speed up a key defence system that fights against tumours, wounds or infections, new research by a multidisciplinary team of mathematicians and biologists from the Universities ...

Deep space radiation treatment reboots brain's immune system

May 21, 2018
Planning a trip to Mars? You'll want to remember your anti-radiation pills.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.